INTS2: The Potential Drug Target and Biomarker (G57508)

Target Name: INTS2

NCBI ID: G57508

INTS2

INTS2: The Potential Drug Target and Biomarker

INTS2 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the immune response and has been implicated in a number of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. As a drug target, INTS2 has the potential to treat a wide range of conditions. In this article, we will explore the potential of INTS2 as a drug target and biomarker.

The Importance of INTS2

INTS2 is a member of the intracellular signaling pathway known as the T-cell signaling pathway. This pathway is involved in the regulation of immune responses, and INTS2 plays a critical role in this process. It is a negative regulator of the T-cell receptor, which is responsible for recognizing and responding to foreign antigens.

Mutations in the INTS2 gene have been linked to a number of diseases, including autoimmune disorders, neurodegenerative disorders, and cancer. For example, INTS2 mutations have been implicated in the development of multiple sclerosis, a neurodegenerative disorder that affects the central nervous system.

In addition to its role in immune regulation, INTS2 is also involved in the regulation of cell survival and metabolism. It has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die when they are no longer needed.

The Potential of INTS2 as a Drug Target

The potential of INTS2 as a drug target is due to its involvement in a wide range of diseases and its critical role in the immune system.

One of the main targets of INTS2 is the regulation of neurodegenerative disorders. INTS2 has been shown to play a role in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its role in neurodegenerative disorders, INTS2 has also been shown to be involved in the development of cancer. For example, INTS2 has been shown to play a role in the regulation of cell proliferation and the development of cancer cells.

Another potential target of INTS2 is the regulation of autoimmune disorders. INTS2 has been shown to play a role in the regulation of T-cell responses, which are a critical part of the immune system.

The Potential of INTS2 as a Biomarker

INTS2 has also been shown to be a potential biomarker for a wide range of diseases. For example, INTS2 has been shown to be involved in the regulation of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its role in neurodegenerative disorders, INTS2 has also been shown to be involved in the regulation of cancer. For example, INTS2 has been shown to play a role in the regulation of cell proliferation and the development of cancer cells.

Conclusion

INTS2 is a protein that is involved in a wide range of diseases and has the potential to be a drug target and biomarker. Its role in immune regulation and its involvement in the regulation of neurodegenerative disorders, cancer, and autoimmune disorders make it an attractive target for research and development. Further studies are needed to fully understand the potential of INTS2 as a drug target and biomarker.

Protein Name: Integrator Complex Subunit 2

Functions: Component of the Integrator (INT) complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes (Probable). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the INT complex (PubMed:23904267)

The "INTS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets